Menu
GWAS Study

Genome-wide association study implicates CHRNA2 in cannabis use disorder.

Demontis D, Rajagopal VM, Thorgeirsson TE et al.

31209380 PubMed ID
GWAS Study Type
51372 Participants
Scroll to explore
Chapter I

Publication Details

Comprehensive information about this research publication

Authors

DD
Demontis D
RV
Rajagopal VM
TT
Thorgeirsson TE
AT
Als TD
GJ
Grove J
LK
Leppälä K
GD
Gudbjartsson DF
PJ
Pallesen J
HC
Hjorthøj C
RG
Reginsson GW
TT
Tyrfingsson T
RV
Runarsdottir V
QP
Qvist P
CJ
Christensen JH
BJ
Bybjerg-Grauholm J
BM
Bækvad-Hansen M
HL
Huckins LM
SE
Stahl EA
TA
Timmermann A
AE
Agerbo E
HD
Hougaard DM
WT
Werge T
MO
Mors O
MP
Mortensen PB
NM
Nordentoft M
DM
Daly MJ
SH
Stefansson H
SK
Stefansson K
NM
Nyegaard M
BA
Børglum AD
Chapter II

Abstract

Summary of the research findings

Cannabis is the most frequently used illicit psychoactive substance worldwide; around one in ten users become dependent. The risk for cannabis use disorder (CUD) has a strong genetic component, with twin heritability estimates ranging from 51 to 70%. Here we performed a genome-wide association study of CUD in 2,387 cases and 48,985 controls, followed by replication in 5,501 cases and 301,041 controls. We report a genome-wide significant risk locus for CUD (P = 9.31 × 10-12) that replicates in an independent population (Preplication = 3.27 × 10-3, Pmeta-analysis = 9.09 × 10-12). The index variant (rs56372821) is a strong expression quantitative trait locus for cholinergic receptor nicotinic α2 subunit (CHRNA2); analyses of the genetically regulated gene expression identified a significant association of CHRNA2 expression with CUD in brain tissue. At the polygenic level, analyses revealed a significant decrease in the risk of CUD with increased load of variants associated with cognitive performance. The results provide biological insights and inform on the genetic architecture of CUD.

35,006 Danish ancestry cases, 16,366 Danish ancestry controls

Chapter III

Study Statistics

Key metrics and study information

51372
Total Participants
GWAS
Study Type
Yes
Replicated
5,501 Icelandic ancestry cases, 301,041 Icelandic ancestry controls
Replication Participants
European
Ancestry
Denmark, Iceland
Recruitment Country
Chapter IV

Analysis

Comprehensive review of health and genetic findings

Important Disclaimer: This review has been performed semi-automatically and is provided for informational purposes only. While we strive for accuracy, this analysis may contain errors, omissions, or misinterpretations of the original research. DNA Genics disclaims all liability for any inaccuracies, errors, or consequences arising from the use of this information. Users should independently verify all information and consult original research publications before making any decisions based on this content. This analysis is not intended as a substitute for professional scientific review or medical advice.

Analysis In Progress

Our analysis of this publication is currently being prepared. Please check back soon for comprehensive insights into the health and genetic findings discussed in this research.